Literature DB >> 35221825

Improving Thrombolysis for Acute Ischemic Stroke: The Implementation and Evaluation of a Theory-Based Resource Integration Project in China.

Qian Fu1, Xiaojun Wang2, Donglan Zhang3, Lu Shi4, Wei Wang5, Zhangbao Guo1,2,3,4,5, Ping Shan5, Guohua Chen5, Zhanchun Feng1.   

Abstract

INTRODUCTION: Intravenous thrombolysis for acute ischemic stroke remains underused in the developing countries. In 2016, a theory-based resource integration project was initiated at a major stroke center in China. This report describes the implementation process and results of the quality improvement project. DESCRIPTION: Eighteen environment-tailored interventions were implemented, including stroke code activation, electronic wristband bundling, structured information sharing, etc. The project was implemented from July 2016 to June 2017. A total of 519 acute ischemic stroke patients were included. After the intervention, median DNT decreased from 62 min to 37 min (P < 0.001). The percentage of cases treated within 30, 45 or 60 minutes increased from 2.5%, 17.4% and 44.6% to 27.4%, 69.4% and 84.7% respectively (P < 0.001). The median length of inpatient stay decreased from 10 days to 8 days (P < 0.001). The proportion of patients with severe disability decreased from 25.5% to 15.8% post-intervention. DISCUSSION: Adequate pre-intervention activities are important conditions for the smooth implementation of the complex service integration initiative. The new treatment pathway has undergone a process of destruction, remodeling and solidification before stable and effective operation. In order to realize the full effect of service integration, whole society efforts are also required.
CONCLUSIONS: Introduction of the theory-based resource integration project was associated with increased thrombolysis administrations, shorter DNT, and no statistically significant change in adverse outcomes. The basic principles of this project might be applicable to various resource settings. Copyright:
© 2022 The Author(s).

Entities:  

Keywords:  door-to-needle time; emergency medical services; ischemic stroke; thrombolysis

Year:  2022        PMID: 35221825      PMCID: PMC8833266          DOI: 10.5334/ijic.5616

Source DB:  PubMed          Journal:  Int J Integr Care            Impact factor:   5.120


  35 in total

1.  Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR).

Authors:  Yilong Wang; Xiaoling Liao; Xingquan Zhao; David Z Wang; Chunxue Wang; Mai N Nguyen-Huynh; Yong Zhou; Liping Liu; Xianwei Wang; Gaifen Liu; Hao Li; Yongjun Wang
Journal:  Stroke       Date:  2011-04-21       Impact factor: 7.914

Review 2.  Stroke: advances in thrombolysis.

Authors:  Markku Kaste
Journal:  Lancet Neurol       Date:  2013-01       Impact factor: 44.182

3.  Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke.

Authors:  Ying Xian; Haolin Xu; Barbara Lytle; Jason Blevins; Eric D Peterson; Adrian F Hernandez; Eric E Smith; Jeffrey L Saver; Steven R Messé; Mary Paulsen; Robert E Suter; Mathew J Reeves; Edward C Jauch; Lee H Schwamm; Gregg C Fonarow
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2017-01

4.  Use of Emergency Medical Services and Timely Treatment Among Ischemic Stroke.

Authors:  Hong-Qiu Gu; Zhen-Zhen Rao; Xin Yang; Chun-Juan Wang; Xing-Quan Zhao; Yi-Long Wang; Li-Ping Liu; Cai-Yun Wang; Chelsea Liu; Hao Li; Zi-Xiao Li; Rui-Ping Xiao; Yong-Jun Wang
Journal:  Stroke       Date:  2019-04       Impact factor: 7.914

5.  Treatment Delays for Patients With Acute Ischemic Stroke in an Iranian Emergency Department: A Retrospective Chart Review.

Authors:  Hadi Hassankhani; Amin Soheili; Samad S Vahdati; Farough A Mozaffari; Justin F Fraser; Neda Gilani
Journal:  Ann Emerg Med       Date:  2018-10-11       Impact factor: 5.721

6.  Thrombolytic therapy in acute ischemic stroke in Asia: The first prospective evaluation.

Authors:  Nijasri C Suwanwela; Kammant Phanthumchinda; Yuttachai Likitjaroen
Journal:  Clin Neurol Neurosurg       Date:  2005-11-09       Impact factor: 1.876

7.  Thrombolysis and clinical outcome in patients with stroke after implementation of the Tyrol Stroke Pathway: a retrospective observational study.

Authors:  Johann Willeit; Theresa Geley; Johannes Schöch; Heinrich Rinner; Andreas Tür; Hans Kreuzer; Norbert Thiemann; Michael Knoflach; Thomas Toell; Raimund Pechlaner; Karin Willeit; Natalie Klingler; Silvia Praxmarer; Michael Baubin; Gertrud Beck; Klaus Berek; Christian Dengg; Klaus Engelhardt; Thomas Erlacher; Thomas Fluckinger; Wilhelm Grander; Josef Grossmann; Hermann Kathrein; Norbert Kaiser; Benjamin Matosevic; Heinrich Matzak; Markus Mayr; Robert Perfler; Werner Poewe; Alexandra Rauter; Gudrun Schoenherr; Hans-Robert Schoenherr; Adolf Schinnerl; Heinrich Spiss; Theresa Thurner; Gernot Vergeiner; Philipp Werner; Ewald Wöll; Peter Willeit; Stefan Kiechl
Journal:  Lancet Neurol       Date:  2014-11-28       Impact factor: 44.182

8.  Simple text-messaging intervention is associated with improved door-to-needle times for acute ischemic stroke.

Authors:  Molly M Burnett; Lara Zimmermann; Zlatan Coralic; Tina Quon; William Whetstone; Anthony S Kim
Journal:  Stroke       Date:  2014-10-28       Impact factor: 7.914

9.  Prevalence, Incidence, and Mortality of Stroke in China: Results from a Nationwide Population-Based Survey of 480 687 Adults.

Authors:  Wenzhi Wang; Bin Jiang; Haixin Sun; Xiaojuan Ru; Dongling Sun; Linhong Wang; Limin Wang; Yong Jiang; Yichong Li; Yilong Wang; Zhenghong Chen; Shengping Wu; Yazhuo Zhang; David Wang; Yongjun Wang; Valery L Feigin
Journal:  Circulation       Date:  2017-01-04       Impact factor: 29.690

10.  Temporal Trends in Intravenous Thrombolysis in Acute Ischemic Stroke: Experience from a Tertiary Care Center in India.

Authors:  Dheeraj Khurana; Biplab Das; Ashok Kumar; Amith Kumar S; Niranjan Khandelwal; Vivek Lal; Sudesh Prabhakar
Journal:  J Stroke Cerebrovasc Dis       Date:  2017-02-22       Impact factor: 2.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.